Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 27, Issue 4, pp. 1037-1047
PubMed
Published By
Print ISSN
Online ISSN
History
- Received September 2, 2020
- Revision received October 27, 2020
- Accepted November 30, 2020
- Published first December 3, 2020.
Article Versions
- Previous version (December 3, 2020 - 06:43).
- Previous version (January 5, 2021 - 05:33).
- You are viewing the most recent version of this article.
Copyright & Usage
©2020 American Association for Cancer Research.
Author Information
- Anne Montfort1,2,
- Thomas Filleron3,4,
- Mathieu Virazels1,2,
- Carine Dufau1,2,5,
- Jean Milhès1,2,
- Cécile Pagès4,6,
- Pascale Olivier7,
- Maha Ayyoub1,4,5,
- Muriel Mounier3,4,
- Amélie Lusque3,4,
- Stéphanie Brayer1,2,6,
- Jean-Pierre Delord1,4,5,
- Nathalie Andrieu-Abadie1,2,
- Thierry Levade1,2,5,8,
- Céline Colacios1,2,5,
- Bruno Ségui1,2,5,#,*, and
- Nicolas Meyer1,2,4,5,6,#,*
- 1INSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.
- 2Equipe Labellisée Fondation ARC pour la recherche sur le cancer, Toulouse, France.
- 3Methodology, biostatistics and clinical operations, Institut Claudius Regaud, IUCT-O, Toulouse, France.
- 4Institut Universitaire du Cancer (IUCT-O), Toulouse, France.
- 5Université Toulouse III - Paul Sabatier, Toulouse, France.
- 6Service d'Oncodermatologie, IUCT-O, CHU de Toulouse, Toulouse, France.
- 7Service de Pharmacologie médicale et clinique, Centre Régional de Pharmacovigilance, de Pharmacoépidémiologie et d'information sur le médicament du CHU de Toulouse, Toulouse, France.
- 8Laboratoire de Biochimie, Institut Fédératif de Biologie, CHU Purpan, Toulouse, France.
- ↵*Corresponding Authors:
Bruno Ségui, Cancer Research Center of Toulouse, 2 avenue Hubert Curien, CS 53717, Toulouse Cedex 1 31037, France. Phone: 33 5-8274-1621; Fax: 335-8274-1685; E-mail: bruno.segui{at}inserm.fr; and Nicolas Meyer, Skin Cancer Unit, Institut Universitaire du Cancer and CHU, 1 rue Irène Joliot-Curie, 31059 Toulouse Cedex 09, France. Phone: 33 5-3115-6034; Fax: 33 5-3115-6033; E-mail: meyer.n{at}chu-toulouse.fr
↵#B. Ségui and N. Meyer contributed equally to this article.
February 2021
Volume 27, Issue 4
Volume 27, Issue 4
Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial
Jump to section
Advertisement